Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Insight Molecular Diagnostics Inc. (iMDx) reported a net loss of $19.1 million for the nine months ended September 30, 2026, an improvement from a $27.3 million loss in the prior year period. The company's financial position remains under pressure with a total shareholders' deficit of $24.2 million and a significant contingent consideration liability of $35.3 million.
Beasley Broadcast Group reported a significant net income of $75.4 million for the nine months ended September 30, 2026, primarily driven by a $91.8 million gain on debt restructure. However, the company faced operational challenges, including a $13.1 million FCC license impairment loss and a decline in net revenue from $152.9 million to $129.5 million year-over-year.
Elite Performance Holding Corp. reported zero revenue for the nine months ended September 30, 2026, resulting in a net loss of $784,601. The company's financial position remains strained with a total stockholders' deficit of $3,653,505 and total liabilities of $3,773,501 against only $119,996 in total assets.
Empire Petroleum reported third quarter 2026 financial results with total product revenue of $10.4 million and a net loss of $3.5 million. Operationally, the company advanced its Texas development program in the Fort Trinidad Field, successfully re-entering the Wakefield-Harrison GU B #1 well to a depth of 21,006 feet to evaluate deep productive zones.
Apimeds Pharmaceuticals US, Inc. reported a net loss of $21.6 million for the nine months ended September 30, 2026, compared to a $4.8 million loss in the prior year. The company transitioned its operations, recording its first software development revenue of $2.48 million while managing a significant digital asset portfolio valued at $142.4 million.
Renasant Corporation has filed its Third Quarter 2026 Investor Presentation, which management will use for meetings with investors during the fourth quarter of 2026. The presentation provides updates on the company's financial performance, business strategy, and objectives.
Research Solutions reported total revenue of $11.9 million for the quarter ended September 30, 2026, a slight decrease from $12.3 million in the prior year, though net income improved to $765,252. The company continues to transition towards its SaaS Platform business, which saw revenue growth, while Transaction-based revenue declined.
Blue Dolphin Energy Company reported 14,921,968 shares of common stock outstanding as of November 16, 2026. The filing highlights a significant corporate structure where Jonathan Carroll and LEH affiliates own 85.1% of the company, and notes the reunification of BOEM and BSEE into the Marine Minerals Administration effective July 2026.
Onfolio Holdings reported a significant decrease in total revenue to $4.7 million for the nine months ended September 30, 2026, compared to $8.7 million in the prior year. The company experienced a substantial net loss driven by a massive $15.2 million interest expense, contributing to an accumulated deficit of over $42 million.
GT Biopharma reported a net loss of $10.88 million for the nine months ended September 30, 2026, compared to a loss of $22.65 million in the prior year period. The company transitioned to a fully remote model as of July 2024 and maintained a cash balance of $9.92 million as of the reporting date.
Perfect Moment Ltd. reported a net loss of $5.58 million for the six months ended September 30, 2026, a slight improvement from the $5.66 million loss in the prior year period. Total assets increased to $18.27 million from $12.23 million, primarily driven by higher inventory levels and accounts receivable, while the company's shareholders' deficit widened to $3.91 million.
Neuphoria Therapeutics Inc., formerly Bionomics Limited, completed its re-domiciliation from Australia to Delaware in December 2024. As of November 13, 2026, the company reported 5,411,334 shares of common stock outstanding and is currently pursuing a proposed merger with Scancell Holdings plc.
Biotricity Inc. reported revenue of $8.61 million for the six months ended September 30, 2026, a 11% increase year-over-year. Despite achieving positive income from operations of $0.50 million, the company recorded a net loss attributable to common stockholders of $2.02 million due to significant interest expenses and derivative liability adjustments.
Automatic Data Processing, Inc. held its Annual Meeting of Stockholders on November 11, 2026. Shareholders elected 13 directors to the board, approved executive compensation on an advisory basis, and ratified the appointment of Deloitte & Touche LLP as the independent accounting firm for the fiscal year beginning July 1, 2026.
Metagenomi Therapeutics, Inc. has furnished a corporate presentation dated November 2026 to provide an update on its precision gene editing pipeline and strategic priorities. The presentation highlights the company's lead candidate MGX-001, upcoming IND filings, and the design of the INTEGR8 clinical trial.
Insight Molecular Diagnostics reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center to support its decentralized testing thesis.
Gold.com, Inc. held its 2026 Annual Meeting of Stockholders on November 12, 2026, where shareholders elected ten directors to serve until the 2027 Annual Meeting. Stockholders also approved, on an advisory basis, the fiscal year 2026 compensation of the company's named executive officers with approximately 91.3% of votes cast in favor.
James Donovan retired as First Senior Vice President and Chief Lending Officer of Unity Bank, receiving a $182,000 lump-sum severance payment. Minsu Kim, previously the Bank's Chief Credit Officer, was appointed as the new Chief Lending Officer effective November 12, 2026. The company has commenced a search for a new Chief Credit Officer to fill the vacancy left by Kim's promotion.
Origin Bancorp, Inc. has appointed Derek McGee as Chief Operating Officer, effective November 13, 2026. McGee, who joined the company in 2022 as Chief Legal Counsel, will now oversee legal, enterprise risk, and regulatory coordination functions. The company stated that McGee will not receive any additional compensation or benefits as a result of this promotion.
Community Trust Bancorp, Inc. (CTBI) is presenting at the Piper Sandler Financial Services Conference in Aventura, Florida on November 17, 2026. The company filed a formal investor presentation deck (Exhibit 99.1) containing current and historical financial results along with future performance goals.
Pro-Dex, Inc. entered into an amendment to its credit agreement with UMB Bank to consolidate the outstanding principal balances of two term notes into a single $8.51 million Term Note D. The amendment extends the maturity date to November 1, 2031, sets a fixed interest rate of 6.67% per annum, and extends the maturity of its revolving note to December 31, 2028.
Hancock Whitney M&A Deal with Trustmark Corporation
Hancock Whitney Corporation has entered into a definitive agreement to acquire Trustmark Corporation in an all-stock merger. Trustmark shareholders will receive 0.7463 shares of Hancock Whitney common stock for each share of Trustmark they own. Following the merger, Trustmark Bank will be merged into Hancock Whitney Bank, and five Trustmark directors will join the Hancock Whitney board.
Independent Bank Corp. filed an investor presentation deck to be used at the Piper Sandler Financial Services Conference on November 17, 2026. The presentation highlights the company's $25.0 billion in total assets, its recent acquisition of Enterprise, and record operating EPS of $1.90 for the third quarter of 2026.
Insight Molecular Diagnostics (iMDx) reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center and the appointment of a new transplant sales leader to prepare for commercial launch.
MIRA Pharmaceuticals announced new pharmacological findings for its investigational oral drug candidate MIRA-55, demonstrating high receptor selectivity for CB2 over opioid and COX receptors. The expanded screening showed a 500-fold separation from opioid receptor interactions, supporting its development as a differentiated non-opioid treatment for inflammatory pain. The company is currently advancing IND-enabling activities with a target submission date in the first half of 2027.
Insight Molecular Diagnostics (iMDx) reported Q3 2026 revenue of $559,000 and provided an update on its FDA de novo submission for GraftAssureDx. The company initiated patient enrollment in its GALACTIC registry study at UCLA Medical Center and appointed a new sales leader to prepare for a potential commercial launch.
Entrepreneur Universe Bright Group Financial Results
Entrepreneur Universe Bright Group reported Q3 2026 revenue of $0.68 million, a decrease from $1.22 million in the prior year period, resulting in a net loss of $0.22 million. The company noted contracting demand in certain consulting lines but saw initial contributions from its newly established Credit Services segment in Hong Kong.
Term
Q3 2026
“Our third quarter results reflected contracting demand in certain consulting service lines, while digital marketing services and our newly established Credit Services segment contributed revenue during the period. We will continue to manage our operations prudently, strengthen our service capabilities and pursue opportunities to expand our revenue base in line with our long-term business objectives.”
Independence Realty Trust, Inc. (IRT) has filed a slide presentation to be used in various upcoming investor meetings beginning November 16, 2026. The presentation is furnished under Item 7.01 as a Regulation FD disclosure to provide strategic and operational updates to the investment community.
W.W. Grainger $400M Debt Financing with J.P. Morgan Securities LLC
W.W. Grainger, Inc. priced an underwritten public offering of $400 million in 5.400% Senior Notes due 2031. The company entered into an underwriting agreement with J.P. Morgan, U.S. Bancorp, and Wells Fargo, with the offering expected to close on November 19, 2026.
Value
$400M
Counterparty
J.P. Morgan Securities LLC, U.S. Bancorp Investments, Inc., and Wells Fargo Securities, LLC
Kyntra Bio reported Q3 2026 financial results, highlighting a cash position of $44.1 million and a runway extended into 2028. The company announced the discontinuation of its FG-3246 and FG-3180 programs due to insufficient efficacy, shifting focus toward a planned Phase 3 trial for roxadustat in early 2027. Additionally, the company restructured a royalty financing agreement, reducing its maximum payment obligation by $60 million.
Term
Q3 2026
“Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial. We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial.”
Thane Wettig, Chief Executive Officer of Kyntra Bio